BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.

The gray market is awash with BPC-157, a drug hyped as a cure-all, but unapproved by the FDA. Will RFK Jr. change that?

An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context, published pricing disclosures, telehealth ...

Debated is the genesis of the first direct-to-consumer (DTC) drug concept in the U.S. Going back to at least 2011, Pfizer’s “unorthodox” ...

Carefully timed bursts of carbon dioxide are emerging as a surprising tool to help the brain wash away toxic proteins linked ...

Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At ...

In a pine forest on Michigan’s Upper Peninsula, the only active nickel mine in the US is nearing the end of its life. At a ...

Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Eric's career includes extensive work in ...

Certain times—and workouts—are better than others.

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...